theHeart.org: Lipid and Metabolic news related to heart conditions.

L'article en question ne peut etre trouvé. Essayer une autre fois ou contacter administrateur du site.

Lipid/Metabolic

Alpha Omega Trial: n-3 fatty acids fail to reduce cardiovascular events in post-MI patients

14 COMMENT S - Aug 29, 2010 02:00 EDT

UPDATED WITH COMMENTARY // The investigators say the negative findings are likely the result of the optimal medical therapy that patients in the trial were receiving following their index MI. All patients were treated with "state-of-the-art" therapy and this might explain the discrepancy with previous studies that suggested n-3 fatty acids, particularly EPA, might be cardioprotective following MI.

Stockholm, Sweden (updated) - A large trial testing the effectiveness of n-3 fatty acids has shown that low-dose supplementation with eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or plant-derived alpha-linolenic acid (ALA) failed to reduce cardiovascular events in a large cohort of patients who had previously had an MI [1].
Read full article »

News

STS registry data on bypass surgery published for consumers

Sep 8, 2010 17:30 EDT

Lipid/Metabolic

UK experts advised rosiglitazone withdrawal in July

Sep 8, 2010 15:30 EDT

Acute Coronary Syndromes

Nurse program provides good RESPONSE for ACS secondary prevention

Sep 3, 2010 13:15 EDT

Medscape Medical News

SCOUT: Sibutramine linked to increased risk of nonfatal vascular events in subjects with preexisting cardiovascular conditions

Sep 3, 2010 09:00 EDT